TY - JOUR
T1 - Synergistic effect of compounds directed to triosephosphate isomerase, a combination to develop drug against trichomoniasis
AU - Benítez-Cardoza, Claudia G.
AU - Brieba, Luis G.
AU - Arroyo, Rossana
AU - Rojo-Domínguez, Arturo
AU - Vique-Sánchez, José L.
N1 - Publisher Copyright:
© 2022 Deutsche Pharmazeutische Gesellschaft.
PY - 2022/6
Y1 - 2022/6
N2 - The development of new drugs is continuous in the world; currently, saving resources (both economic ones and time) and preventing secondary effects have become a necessity for drug developers. Trichomoniasis is the most common nonviral sexually transmitted infection affecting more than 270 million people around the world. In our research group, we focussed on developing a selective and more effective drug against Trichomonas vaginalis, and we previously reported on a compound, called A4, which had a trichomonacidal effect. Later, we determined another compound, called D4, which also had a trichomonacidal effect together with favorable toxicity results. Both A4 and D4 are directed at the enzyme triosephosphate isomerase. Thus, we made combinations between the two compounds, in which we determined a synergistic effect against T. vaginalis, determining the IC50 and the toxicity of the best relationship to obtain the trichomonacidal effect. With these results, we can propose a combination of compounds that represents a promising alternative for the development of a new therapeutic strategy against trichomoniasis.
AB - The development of new drugs is continuous in the world; currently, saving resources (both economic ones and time) and preventing secondary effects have become a necessity for drug developers. Trichomoniasis is the most common nonviral sexually transmitted infection affecting more than 270 million people around the world. In our research group, we focussed on developing a selective and more effective drug against Trichomonas vaginalis, and we previously reported on a compound, called A4, which had a trichomonacidal effect. Later, we determined another compound, called D4, which also had a trichomonacidal effect together with favorable toxicity results. Both A4 and D4 are directed at the enzyme triosephosphate isomerase. Thus, we made combinations between the two compounds, in which we determined a synergistic effect against T. vaginalis, determining the IC50 and the toxicity of the best relationship to obtain the trichomonacidal effect. With these results, we can propose a combination of compounds that represents a promising alternative for the development of a new therapeutic strategy against trichomoniasis.
KW - Trichomonas vaginalis
KW - docking
KW - synergistic effect
KW - triosephosphate isomerase
UR - http://www.scopus.com/inward/record.url?scp=85127283077&partnerID=8YFLogxK
U2 - 10.1002/ardp.202200046
DO - 10.1002/ardp.202200046
M3 - Artículo
C2 - 35332589
AN - SCOPUS:85127283077
SN - 0365-6233
VL - 355
JO - Archiv der Pharmazie
JF - Archiv der Pharmazie
IS - 6
M1 - 2200046
ER -